Compare · DERM vs NVO
DERM vs NVO
Side-by-side comparison of Journey Medical Corporation (DERM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DERM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $205.41B, about 1160.2x DERM ($177.0M).
- Over the past year, DERM is down 9.1% and NVO is down 8.2% - NVO leads by 1.0 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for DERM).
- NVO has more recent analyst coverage (25 ratings vs 7 for DERM).
- Company
- Journey Medical Corporation
- Novo Nordisk A/S
- Price
- $6.61+3.77%
- $46.73+0.74%
- Market cap
- $177.0M
- $205.41B
- 1M return
- -9.02%
- -7.54%
- 1Y return
- -9.15%
- -8.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 7
- 25
Journey Medical Corporation
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DERM
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation
- Director Toledano Miranda Jayne was granted 50,000 shares, increasing direct ownership by 42% to 168,618 units (SEC Form 4)
- Director Smith Justin Adam was granted 50,000 shares, increasing direct ownership by 28% to 231,618 units (SEC Form 4)
- Director Herskowitz Neil was granted 50,000 shares, increasing direct ownership by 42% to 168,618 units (SEC Form 4)
- Director Toledano Miranda Jayne was granted 10,000 shares, increasing direct ownership by 9% to 118,618 units (SEC Form 4)
- Director Smith Justin Adam was granted 10,000 shares, increasing direct ownership by 6% to 181,618 units (SEC Form 4)
Latest NVO
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S